Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares IssuedShares OutstandingShares Outstanding
Ratios

Silence Therapeutics (SLN) Accumulated Depreciation & Amortization (2023 - 2025)

Silence Therapeutics' Accumulated Depreciation & Amortization history spans 3 years, with the latest figure at $4.0 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 12.46% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.0 million, a 12.46% decrease, with the full-year FY2025 number at $4.0 million, down 12.46% from a year prior.
  • Accumulated Depreciation & Amortization hit $4.0 million in Q4 2025 for Silence Therapeutics, down from $4.5 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for SLN hit a ceiling of $4.5 million in Q4 2024 and a floor of $4.0 million in Q4 2025.
  • Historically, Accumulated Depreciation & Amortization has averaged $4.2 million across 3 years, with a median of $4.2 million in 2023.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 8.1% in 2024 and later fell 12.46% in 2025.
  • Tracing SLN's Accumulated Depreciation & Amortization over 3 years: stood at $4.2 million in 2023, then rose by 8.1% to $4.5 million in 2024, then dropped by 12.46% to $4.0 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for SLN at $4.0 million in Q4 2025, $4.5 million in Q4 2024, and $4.2 million in Q4 2023.